Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...
Switzerland’s top criminal court convicted a multinational company for the first time, ruling against commodities trader ...
Swiss banking giant UBS on Tuesday posted $770 million in fourth-quarter net profit, launching a $1 billion share buyback ...
By Ariane Luthi ZURICH (Reuters) -Swiss bank Julius Baer plans to cut its workforce by about 5% under new chief executive ...
KfW became the 14th SSA issuer to visit the Swiss franc bond market this year on Thursday, ending a 15-year absence from the ...
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...
ZURICH, Feb 6 (Reuters) - UBS would be seriously weakened and forced to consider its strategy if Swiss rules required it to hold 25 billion Swiss francs ($27.69 billion) more in additional capital, ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.
Analysts at Rabobank predict the Euro to Swiss franc exchange rate (EUR/CHF) will face downward pressure in the coming months. According to analysts at CIBC Capital Markets, following the ...
Analysts at Rabobank predict the Euro to Swiss franc exchange rate (EUR/CHF) will face downward pressure in the coming months. According to analysts at CIBC Capital Markets, following the ...
UBS Group AG said it aims to buy back up to $3 billion of its own shares this year, signaling confidence as it awaits a crucial regulatory ruling on its capital levels.